[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 420,945
  • Shares Outstanding, K 60,135
  • Annual Sales, $ 216,110 K
  • Annual Income, $ -220,470 K
  • EBIT $ -144 M
  • EBITDA $ -134 M
  • 60-Month Beta 0.65
  • Price/Sales 1.98
  • Price/Cash Flow N/A
  • Price/Book 1.28

Options Overview Details

View History
  • Implied Volatility 113.39% (+41.74%)
  • Historical Volatility 47.45%
  • IV Percentile 81%
  • IV Rank 28.10%
  • IV High 332.52% on 11/14/25
  • IV Low 27.75% on 09/04/25
  • Expected Move (DTE 11) 0.21 (2.81%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 911
  • Volume Avg (30-Day) 516
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 15,831
  • Open Int (30-Day) 17,132
  • Expected Range 7.35 to 7.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.53
  • Number of Estimates 2
  • High Estimate $-0.49
  • Low Estimate $-0.57
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -6.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.55 +15.42%
on 04/24/26
7.79 -2.95%
on 04/08/26
+0.56 (+8.00%)
since 04/02/26
3-Month
5.73 +31.94%
on 02/20/26
9.94 -23.94%
on 03/10/26
-0.04 (-0.53%)
since 02/04/26
52-Week
3.81 +98.47%
on 05/15/25
9.94 -23.94%
on 03/10/26
+2.99 (+65.43%)
since 05/02/25

Most Recent Stories

More News
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUSâ„¢ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

WASHINGTON , May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUSâ„¢ (tradipitant) is now commercially available across the United States for...

VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUSâ„¢ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

WASHINGTON , May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUSâ„¢ (tradipitant) is now commercially available across the United States for...

VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Conference Call and Webcast to Follow

VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

WASHINGTON , April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab...

ANAB : 69.78 (+4.52%)
VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

WASHINGTON , April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22,...

VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

WASHINGTON , April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification....

VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUSâ„¢ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

WASHINGTON , April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUSâ„¢ (tradipitant) for the...

VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

WASHINGTON , March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing,...

VNDA : 7.56 (+8.00%)
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

WASHINGTON , March 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for...

VNDA : 7.56 (+8.00%)
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

WASHINGTON , Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami...

VNDA : 7.56 (+8.00%)

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 8.09
2nd Resistance Point 7.84
1st Resistance Point 7.70
Last Price 7.56
1st Support Level 7.31
2nd Support Level 7.06
3rd Support Level 6.92

See More

52-Week High 9.94
Fibonacci 61.8% 7.60
Last Price 7.56
Fibonacci 50% 6.87
Fibonacci 38.2% 6.15
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.